Scott M. Terrillion
Net Worth
Last updated:
What is Scott M. Terrillion net worth?
The estimated net worth of Mr. Scott M. Terrillion is at least $5,153,488 as of 5 Apr 2024. He owns shares worth $476,499 as insider, has earned $561,829 from insider trading and has received compensation worth at least $4,115,160 in Cara Therapeutics, Inc..
What is the salary of Scott M. Terrillion?
Mr. Scott M. Terrillion salary is $587,880 per year as Chief Compliance Officer, Gen. Counsel & Corporation Sec. in Cara Therapeutics, Inc..
How old is Scott M. Terrillion?
Mr. Scott M. Terrillion is 62 years old, born in 1963.
What stocks does Scott M. Terrillion currently own?
As insider, Mr. Scott M. Terrillion owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Cara Therapeutics, Inc. (CARA) | Chief Compliance Officer, Gen. Counsel & Corporation Sec. | 88,247 | $5.4 | $476,499 |
What does Cara Therapeutics, Inc. do?
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Scott M. Terrillion insider trading
Cara Therapeutics, Inc.
Mr. Scott M. Terrillion has made 17 insider trades between 2018-2024, according to the Form 4 filled with the SEC. Most recently he sold 2,753 units of CARA stock worth $2,285 on 5 Apr 2024.
The largest trade he's ever made was exercising 6,256 units of CARA stock on 3 Mar 2023. As of 5 Apr 2024 he still owns at least 88,247 units of CARA stock.
Cara Therapeutics key executives
Cara Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Derek T. Chalmers D.Sc., Ph.D. (61) Co-Founder & Senior Advisor
- Dr. Frédérique Menzaghi (59) Chief Scientific Officer and Senior Vice President of R&D
- Dr. Joana Goncalves (51) Chief Medical Officer
- Mr. Christopher A. Posner (55) Pres, Chief Executive Officer & Director
- Mr. Richard Makara (54) Vice President, Head of Accounting, Controller & Principal Accounting Officer
- Mr. Scott M. Terrillion (62) Chief Compliance Officer, Gen. Counsel & Corporation Sec.
- Mr. Thomas Charles Reilly (53) Chief Financial Officer